Morgan Stanley’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-45,025
| Closed | -$9.48K | – | 7761 |
|
|
2023
Q2 | $9.48K | Sell |
45,025
-15
| -0% | -$3 | ﹤0.01% | 6831 |
|
|
2023
Q1 | $7.21K | Sell |
45,040
-3,126
| -6% | -$1.39K | ﹤0.01% | 6972 |
|
|
2022
Q4 | $26.7K | Sell |
48,166
-1,146
| -2% | -$975 | ﹤0.01% | 6554 |
|
|
2022
Q3 | $59K | Sell |
49,312
-179,901
| -78% | -$194K | ﹤0.01% | 6338 |
|
|
2022
Q2 | $144K | Sell |
229,213
-18,964
| -8% | -$14.6K | ﹤0.01% | 6072 |
|
|
2022
Q1 | $282K | Buy |
248,177
+147,528
| +147% | +$176K | ﹤0.01% | 5727 |
|
|
2021
Q4 | $227K | Sell |
100,649
-267,642
| -73% | -$672K | ﹤0.01% | 6000 |
|
|
2021
Q3 | $1.26M | Buy |
368,291
+75,265
| +26% | +$232K | ﹤0.01% | 4894 |
|
|
2021
Q2 | $876K | Buy |
293,026
+56,995
| +24% | +$180K | ﹤0.01% | 5164 |
|
|
2021
Q1 | $763K | Buy |
236,031
+218,185
| +1,223% | +$728K | ﹤0.01% | 4896 |
|
|
2020
Q4 | $38K | Sell |
17,846
-17,405
| -49% | -$28.7K | ﹤0.01% | 6242 |
|
|
2020
Q3 | $41K | Buy |
35,251
+25,695
| +269% | +$26.4K | ﹤0.01% | 5796 |
|
|
2020
Q2 | $9K | Buy |
9,556
+1,640
| +21% | +$1.56K | ﹤0.01% | 6196 |
|
|
2020
Q1 | $6K | Buy |
7,916
+236
| +3% | +$274 | ﹤0.01% | 6166 |
|
|
2019
Q4 | $8K | Sell |
7,680
-229
| -3% | -$251 | ﹤0.01% | 6324 |
|
|
2019
Q3 | $8K | Sell |
7,909
-2,492
| -24% | -$3.4K | ﹤0.01% | 6278 |
|
|
2019
Q2 | $19K | Sell |
10,401
-1,484
| -12% | -$2.39K | ﹤0.01% | 5957 |
|
|
2019
Q1 | $23K | Buy |
11,885
+9,044
| +318% | +$13.2K | ﹤0.01% | 5973 |
|
|
2018
Q4 | $4K | Sell |
2,841
-19,904
| -88% | -$35.8K | ﹤0.01% | 6346 |
|
|
2018
Q3 | $62K | Buy |
22,745
+6,027
| +36% | +$12.5K | ﹤0.01% | 5818 |
|
|
2018
Q2 | $32K | Sell |
16,718
-1,431
| -8% | -$2.89K | ﹤0.01% | 6029 |
|
|
2018
Q1 | $38K | Buy |
18,149
+5,465
| +43% | +$11.7K | ﹤0.01% | 5961 |
|
|
2017
Q4 | $26K | Sell |
12,684
-71,686
| -85% | -$149K | ﹤0.01% | 6015 |
|
|
2017
Q3 | $112K | Sell |
84,370
-22,142
| -21% | -$27.5K | ﹤0.01% | 5542 |
|
|
2017
Q2 | $167K | Buy |
106,512
+38,007
| +55% | +$73.3K | ﹤0.01% | 5429 |
|
|
2017
Q1 | $221K | Sell |
68,505
-113,650
| -62% | -$280K | ﹤0.01% | 5279 |
|
|
2016
Q4 | $245K | Buy |
182,155
+144,135
| +379% | +$188K | ﹤0.01% | 5277 |
|
|
2016
Q3 | $60K | Sell |
38,020
-6,153
| -14% | -$9.45K | ﹤0.01% | 5518 |
|
|
2016
Q2 | $59K | Sell |
44,173
-3,038
| -6% | -$14.2K | ﹤0.01% | 5471 |
|
|
2016
Q1 | $249K | Buy |
47,211
+18,719
| +66% | +$115K | ﹤0.01% | 4845 |
|
|
2015
Q4 | $224K | Sell |
28,492
-11,976
| -30% | -$103K | ﹤0.01% | 5034 |
|
|
2015
Q3 | $341K | Sell |
40,468
-134,731
| -77% | -$1.24M | ﹤0.01% | 4818 |
|
|
2015
Q2 | $1.92M | Buy |
175,199
+13,992
| +9% | +$180K | ﹤0.01% | 3671 |
|
|
2015
Q1 | $2.25M | Sell |
161,207
-58,905
| -27% | -$901K | ﹤0.01% | 3489 |
|
|
2014
Q4 | $3.72M | Buy |
220,112
+8,244
| +4% | +$120K | ﹤0.01% | 3002 |
|
|
2014
Q3 | $2.84M | Buy |
211,868
+108,731
| +105% | +$1.29M | ﹤0.01% | 3152 |
|
|
2014
Q2 | $1.31M | Buy |
103,137
+74,523
| +260% | +$776K | ﹤0.01% | 3834 |
|
|
2014
Q1 | $340K | Sell |
28,614
-70,598
| -71% | -$947K | ﹤0.01% | 4816 |
|
|
2013
Q4 | $1.37M | Buy |
99,212
+28,643
| +41% | +$405K | ﹤0.01% | 3690 |
|
|
2013
Q3 | $1.23M | Sell |
70,569
-78,847
| -53% | -$1.51M | ﹤0.01% | 3619 |
|
|
2013
Q2 | $2.42M | Buy |
+149,416
| New | +$4.62M | ﹤0.01% | 3005 |
|
Other funds holding INFI
Morgan Stanley's INFI Position: Q3 2023 in Review
Morgan Stanley sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q3 2023, closing a stake of 45,025 shares — an estimated $9.48K sold.
Morgan Stanley first reported a position in INFI in Q2 2013 and held it in 41 quarters. The position peaked at $3.72M in Q4 2014. 3 funds tracked by Wall St. Rank hold INFI as of Q3 2023.
- Morgan Stanley reported no remaining Infinity Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- Morgan Stanley sold 45,025 Infinity Pharmaceuticals, Inc. shares in Q3 2023, an estimated $9.48K.
- Morgan Stanley first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 41 quarters.
- Morgan Stanley's Infinity Pharmaceuticals, Inc. position peaked at $3.72M in Q4 2014.
- 3 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q3 2023.
Based on Morgan Stanley's 13F filing for Q3 2023, filed 15 Nov 2023.